Chromosomal rearrangements involving 3q26 either due to inversion or translocation with various partner chromosomes are a recurrent finding in malignant myeloid disorders. Typically, these chromosome aberrations contribute to ectopic expression of or to the formation of fusion genes involving the EVI1 proto-oncogene. Chromosomal translocations involving the short arm of chromosome 2 (p15-p23) and the distal part of the long arm of chromosome 3 (q26-q27) are a rare but recurrent finding in patients with myeloid malignancies, and are assumed to be part of this spectrum of disorders. Thus far, however, these translocations have been poorly studied. Here, we present 21 new cases with myelodysplasia, acute myeloid leukemia or CML in blast crisis, which upon karyotyping showed the presence of a t(2;3). Furthermore, an extensive literature review disclosed 29 additional cases. Morphological, clinical and cytogenetic assessment revealed the typical hallmarks of 3q26/EVI1 rearrangements, that is, trilineage dysplasia and dysmegakaryopoiesis, poor prognosis and additional monosomy 7. Molecular cytogenetic analysis and PCR in selected samples indicated that in most cases the translocation indeed targets the EVI1 locus. Mapping of the chromosome 2 breakpoints confirmed the initially suspected cytogenetic breakpoint heterogeneity at the 2p arm.
Introduction
Rearrangements involving chromosome band 3q26 have been identified in 1-2% of acute myeloid leukemia (AML), MDS or blast crisis of CML, and typically present with trilineage dysplasia, dysmegakaryopoiesis, elevated platelet count and adverse outcome. Translocation t(3;3)(q21;q26) or inversion inv(3)(q21q26) are most frequently observed. In these patients, breakpoints are located proximal to the 5 0 -or distal to 3 0 -end of the EVI1 gene, respectively, leading to inappropriate expression of the gene, presumably due to juxtaposition to enhancer sequences of the Ribophorin 1 gene at 3q21. 1, 2 In contrast, translocations t(3;21) and t(3;12) result in EVI1 activation due to gene fusion: CBFA2-EVI1 or ETV6-EVI1, respectively. 2, 3 Chromosomal translocations involving the short arm of chromosome 2 and the distal part of the long arm of chromosome 3 in patients with myeloid disorders have been reported occasionally, but have not been molecularly characterized. Here, we report clinical and cytogenetic findings in 21 new patients with a myeloid malignancy showing the t(2;3) and compare these with 29 reported cases. Breakpoint mapping by fluorescence in situ hybridization (FISH) revealed involvement of the EVI1 locus at 3q26 in most cases and, in addition, 2p-breakpoint heterogeneity.
Materials and methods

Patients
Patients were identified by reviewing cytogenetic data obtained from diagnostic bone marrow preparations of patients with hematological disorders analyzed at six Dutch and two Belgian genetic centers. Cases were selected for further study when a translocation t(2;3)(p15-23;q26-27) was detected in at least one cell line. Clinical data were obtained from medical records and from referring hematologists.
Cell morphology
Morphological studies of the bone marrow specimen taken at diagnosis were performed by the local responsible hematopathologist. Morphologic assessments were performed on Wright-Giemsa preparations and classified according to established FAB criteria [25] [26] [27] for AML and MDS. Dysmegakaryopoiesis was defined as a predominance of hypolobulated megakaryocytes, with or without elevated platelet count.
Cytogenetics
Bone marrow specimens were cultured for cytogenetic analysis by established methods. Metaphases were either G-or Rbanded. Chromosome aberrations are described according to guidelines of an International System for Human Cytogenetic Nomenclature. 28 Fluorescence in situ hybridization A cytogenetic cell suspension (methanol/acetic acid fixed cells kept at À201C) was available from 13 cases for molecular cytogenetic investigation. FISH was performed according to established protocols ( [9] [10] [11] [12] [13] [14] [15] [16] [17] 21) . Whole chromosome painting probes (Cambio, Cambridge, UK) were applied to confirm the presence of a t(2;3). The centromeres of chromosomes 2 and 3 were identified by the cCI2-84 probe 31 and the pa3.5 probes, 32 respectively. For more detailed breakpoint identification, the following cosmid probes were used: cCI2-33 (2p14-p15), cCI2-444 (2p15-p16), cCI2-111 (2p21), cCI2-155 (2p22) mapping on chromosome 2 31 and cCI3-764 (3q27), cCI3-510 (3q25) mapping on chromosome 3, 33 a PAC 264C14 identifying the MDS1 gene at 3q26 was a generous gift from Peter Marynen. B5-2, a cosmid corresponding to BCL-6 gene at 3q27 was also used. 34 In addition, cases 9-17 and 21 were analyzed using three BACs probes mapping at 2p16.1 (RP11-260 K8, RP-11-407F2 and RP11-518G2) and by a tiling path contig of 14 BACs spanning a region of 1.7 Mb including the EVI1 locus at 3q26. 35 These BAC probes were obtained from the Mapping Core Group's clone resources at the Sanger Institute. Probes selected for FISH were: RP11-694D5, RP11-62L21, RP11-48N2, RP11-152C17K, RP11-33A1, RP11-627P8, RP11-82C9, RP11-250A4, RP11-141C22, RP11-115B16, RP11-641D5, RP11-3K16, RP11-816J6 and RP11-362K14. 35 Cosmids and BACs were indirectly labeled with digoxygenin-16-dUTP or with biotin-11-dUTP and visualized using Texas Red or avidine-FITC, respectively. The probes were hybridized in pairs together with a centromeric probe for chromosome 2. Commercial probes for ALK/2p23 and N-MYC/2p24 were used in some cases (Vysis, Downers Grove, IL, USA). Fluorescent signals were visualized either under a Zeiss Axiophot fluorescence microscope using appropriate filters or on a Leica DMRB (Wetzlar, Germany) fluorescence microscope equipped with a triple band pass filter and a cooled black and white chargedcouple device camera (Photometrics, Tucson, AZ) run by Quips Smart Capturet FISH imaging.
Expression analysis of EVI1
Total RNA was extracted from bone marrow using the Trizol reagent (Gibco, BRL) according to the manufacturer's recommendations. RT-PCR for the detection of EVI1 overexpression was performed as described previously. 36 The primers used do not discriminate between MDS1-EVI1 and EVI1 transcripts.
Literature review
Relevant publications were identified through a Medline search , cited references and cases described in the Catalogue of Chromosome Aberrations in Cancer. 37 The search included all patients reported until July 2003, and identified 29 previously published cases of myeloid disorders associated with t(2;3)(p13-23;q26-29). Cases with a B-cell lymphoma and the t(2;3)(p12;q27) 38 were excluded, because this translocation was clearly distinct from the derivative chromosomes 2 and 3 of the patients from the present study.
Results
Clinical, hematological and cytogenetic data of 21 new cases (11 males and 10 females) with myeloid hematological disorder and a t(2;3) are summarized in Tables 1 and 2 .
Except for a 12-year-old child (case 10), all patients were adults, age ranging from 30 to 77 years (median 52 years).
The diagnosis at presentation was AML in 10 cases, MDS in nine and CML blast crisis or in acceleration in two cases (patients 11 and 17). Prominent trilineage dysplasia, 6 months later.
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In the two patients with CML, signs of acceleration were already present at diagnosis. Both patients responded poorly to hydroxyurea (case 11) or to other regimens (case 17). Patient 17 showed dysmegakaryopoiesis at diagnosis and prominent trilineage dysplasia 6 months later, together with excess of blasts and t(2;3) in all 30 metaphases.
The median survival time was 15 months (ranging from 1 to 53). Patients 9, 12, 16 and 17 underwent an allogeneic bone marrow transplantation.
Cytogenetically, the t(2;3) was the sole or the primary change in 11 cases. Recurrent secondary changes were monosomy 7 (three cases), deletion 5q (five times), deletion 7q (two times), while t(9;22) was present in the two patients with CML in blast crisis. Only four cases showed a complex karyotype with more than three independent aberrations.
Based on banding analysis, two types of t(2;3) translocation were discerned: in patients 1-11 and 21, the breakpoint on chromosome 2 was assigned to bands 2p21-p23, while in cases 12-20 a more proximal position at 2p16 (range p15-p21) was defined ( Figure 1) . The breakpoints on chromosome 3 were invariably described at 3q26-q27. The only exception was patient 14, where the breakpoint on 2p was clearly more proximal (2p13) and the 3q breakpoint at the most distal band 3q28. Unfortunately, no material was left for further FISH analysis.
An extensive literature review disclosed 29 cases of myeloid malignancies associated with t(2;3). In many reports, the clinical and hematological data were scarce or absent. In Table 3 , a summary of these data is given in parallel with the findings in the present series. There were 19 cases of AML, of which eight were M2 and myelodysplasia was found in four cases; one patient presented with myelofibrosis in transformation and four with CML in acceleration or blast crisis. Dysmegakaryopoiesis was seen in 13/14 investigated cases and 4/15 cases were reported as therapy related. In addition, some of the AML cases were reported to be secondary to previous MDS. Survival data were available for nine patients and ranged from 1 to 24 months (median 5 months).
The t(2;3) was the sole or the primary aberration in eight cases, monosomy 7 was the most frequent secondary change (11 cases). Deletion 5q (three cases), del 7q (two cases) were also recurrent. In addition, the t(2;3) was seen in four cases of t(9;22) CML. In three instances, the description of the karyotype was incomplete.
FISH analysis of breakpoints
Cosmids and BACs were used for more refined breakpoint mapping of the patients in the present study (Table 4) .
The cytogenetic heterogeneity of the 2p breakpoints was confirmed by FISH: patients 1, 2, 8, 9, 10 and 21 showed a breakpoint distal to 2p16; in patient 12, the breakpoint was located within BAC RP11-407F2 at 2p16.1, in patients 16 and 17, the breakpoint was in BAC RP11-260K8 at 2p16 and in patients 15, 18 and 19, breakpoints mapped proximal to 2p16. 
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Figure 1
Partial RFA-banded karyotype of cases 10 (a) and case 12 (b) with the distal and proximal breakpoint on chromosome 2, respectively.
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For three patients (patients 9, 10, 11), probes for the ALK gene at 2p23 and MYCN at 2p24 were tested and found to be translocated to der(3) as expected.
The breakpoints on chromosome 3 were found to be proximal to MDS1 in eight cases (patients 2, 11, 12, 15, [18] [19] [20] [21] and distal to MDS1 in four cases. For two of the latter cases, breakpoints were cytogenetically assigned to 3q27 (patients 1 and 8), whereas two others were located to 3q26 (patients 9 and 10). In all cases, the BCL-6 probe hybridized to the der(2), and thus the breakpoints were all proximal to BCL-6 at 3q27.
Use of the BAC contigs allowed more precise mapping of the breakpoints in band 3q26 in six cases where a split signal was found upon hybridization with one or two contiguous BACs (Figure 2 ). Only case 15 could not be characterized, since the break appears to be proximal to the 3q26 contig. In fact, case 15 showed unusually proximal breakpoints on chromosome 2 as well as on chromosome 3. In case 12, clones spanning the 2p and 3q breakpoints were identified. The 2p chromosomal breakpoint was shown to reside within RP11-407F2, which contains sequences derived from AK055400, a sequence sharing homology with the neuronal thread protein gene. RT-PCR analyses with primers derived from AK055400 and EVI1 exon 2, however, failed to reveal a fusion transcript.
EVI1 expression
In six patients, material suitable for expression analyses was available. In patients with a chromosomal breakpoint mapping in the vicinity of the EVI1 locus (patients 9, 10, 12, 14 and 21), overexpression of the EVI1 transcript was demonstrated by RT-PCR (Table 2) . In case 15, in which the 3q breakpoint was mapped outside the BAC contig, no EVI1 expression could be detected (not shown).
Discussion
In this study, we have identified 21 patients with a myeloid malignancy and a t(2;3)(p13-23;q26-28) or juxtaposition of 2p13-23 to 3q26-28 regions. Furthermore, we were able to find 29 other cases with similar overall characteristics in the literature. These observations highlight the nonrandom nature of the t(2;3) in myeloid malignancies. There was a broad variation in the type of myeloid malignancy, ranging from RA, RAEB, CML to AML. Trilineage dysplasia and dysmegakaryopoiesis were common features. Furthermore, most of the patients had an unfavorable prognosis. In 11 cases, the t(2;3) was sole or the primary change. In addition, frequent association of the Denominator is the number of cases for which data are available. t(2p;3q) is a nonrandom abnormality in myeloid leukemia M Stevens-Kroef et al Table 4 Hybridization results of locus specific probes to the der(2), der(3) or both (split signal) in metaphases with t(2;3) from our patients (2) der (3) der(3) RP11-260K8 2p16.1 der (2) der (2) der (2) der (3) der (2) a der(3) a der(2) RP11-407F2 2p16.1 der(2) der(2) Split b der (3) der (3) der (3) der(2) RP11-518G12 2p16.1 der (2) der (3) der (3) der (3) der (3) der(2) cC12-111 2p21 der(3) der (2) der(2) cC12-155 2p22 der(3) der(3) 3q cC13-510 3q25 der3) der(3) der(3) 264C14 (MDS1) 3q26 der(3) der(2) der(3) der(3) der(3) der(2) der(2) der(2) der(2) der(2) der(2) cC13-764 3q27 der(3) Split b B5-2 (BCL6) 3q27 der(2) der(2) der(2) der(2) der(2) der(2) der (2) der (2) 3q26 BACs contig RP11-694D5 3q26 der(3) der(3) der(2) der(3)
der (2) der (2) der (2) der (2) der (2) der (2) a In some metaphases there is a weak signal on der(3) (# 16) or on der(2) (# 17), which suggests a breakpoint within these clones. Split signals that hybridize to the der(2) and der(3). c Split signal with major hybridization site on the der(3) or on the der(2). In bold, the probes translocated on the reciprocal derivative ¼ der(3) for 2p probes and der(2) for 3q probes.
t(2p;3q) is a nonrandom abnormality in myeloid leukemia M Stevens-Kroef et al t(2;3) with total or partial loss of chromosomes 5 and/or 7 was noted. Chromosome band 3q26 is the breakpoint site of recurring translocations and inversions observed in patients with myeloid malignancies, for example, inv(3)(q21q26), t(3;3)(q21;q26), ins(3;3)(q26;q21q26), t(3;12)(q26;p13) and t(3;21)(q26;q22). 3, 39 These chromosomal aberrations have been shown to result in transcriptional activation of the EVI1 oncogene. 2, 40 Our assay detects MDS1-EVI and EVI1. Both transcripts have been shown to be expressed in myeloid malignancies with or without 3q26 rearrangement, but with unfavorable cytogenetics and poor outcome. 36, 41 Hematological malignancies displaying EVI1 activation or 3q26 rearrangements exhibit distinct phenotypic characteristics such as a myeloid phenotype, monosomy 7, adverse clinical course, trilineage dysplasia, thrombocytosis, young age at diagnosis and prior therapy with alkylating agents. [41] [42] [43] [44] The recurrent involvement of 3q26 evidently points to a possible involvement of EVI1 in a subset of patients displaying a t(2;3)(p13-23;q26). Indeed, in all but one of our patients, in which expression analyses could be performed, ectopic expression of the EVI1 gene was demonstrated. Therefore, the current report indicates a recurrent involvement of EVI1 in the majority of t(2;3) cases.
The preferential involvement of EVI1 in these rearrangements most probably contributes to the clinical characteristics reported here. Indeed, most of the typical clinical associations associated with EVI1 rearrangements were amply demonstrated in our cases. On the other hand, however, a small proportion of the 2;3 translocation cases did not exhibit ectopic EVI1 expression and showed atypical breakpoints when analyzed by FISH. Therefore, great care should be taken in assigning clinical relevance to the presence of an apparently similar cytogenetic rearrangement. Although the presence of a t(2;3) is an adverse prognostic feature in general, this observation would certainly be biased by the presence of a significant subgroup of patients displaying ectopic EVI1 expression. In this respect, assessment of genomic rearrangement at or near the EVI1 locus and examining the transcriptional activation of the EVI1 gene seems highly relevant.
In contrast to the clustering of translocation breakpoints in the vicinity of the EVI1 locus at 3q26, the chromosome 2 short arm breakpoints in our study displayed a high degree of heterogeneity as demonstrated by both conventional and molecular cytogenetic analyses. In one patient, the 2p breakpoint could be characterized at a molecular level and was shown to disrupt the genomic BAC clone RP11-407F2. However, recurrent involvement of this and surrounding regions in other patients was excluded by FISH. In addition, expression analyses failed to demonstrate the presence of an EVI1 fusion gene in this rearrangement. Based on this observation, and on the observed cytogenetic heterogeneity, we suggest that the 2;3 translocation does not result in the generation of an EVI1 chimera originating from the t(2;3), but instead, that the ectopic expression of EVI1 in these rearrangements results from juxtaposition to or disruption of transcriptional control elements.
In summary, the clinical and molecular features of t(2;3) myeloid malignancies indicate that they belong to the group of patients with 3q26 alteration: indeed, these patients show ectopic expression of EVI1, often exhibit trilineage dysplasia, disturbed megakaryopoiesis and poor prognosis.
